Genetic Signatures Ltd - Asset Resilience Ratio
Genetic Signatures Ltd (GSS) has an Asset Resilience Ratio of 60.91% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Genetic Signatures Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Genetic Signatures Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Genetic Signatures Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Genetic Signatures Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genetic Signatures Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.19 Million | 35.05% |
| Short-term Investments | AU$12.68 Million | 25.86% |
| Total Liquid Assets | AU$29.87 Million | 60.91% |
Asset Resilience Insights
- Very High Liquidity: Genetic Signatures Ltd maintains exceptional liquid asset reserves at 60.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genetic Signatures Ltd Industry Peers by Asset Resilience Ratio
Compare Genetic Signatures Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Genetic Signatures Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Genetic Signatures Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 43.61% | AU$23.82 Million ≈ $16.86 Million |
AU$54.63 Million ≈ $38.65 Million |
-4.55pp |
| 2024-06-30 | 48.15% | AU$32.40 Million ≈ $22.93 Million |
AU$67.29 Million ≈ $47.61 Million |
+27.78pp |
| 2023-06-30 | 20.38% | AU$10.00 Million ≈ $7.08 Million |
AU$49.08 Million ≈ $34.73 Million |
-21.53pp |
| 2022-06-30 | 41.91% | AU$25.00 Million ≈ $17.69 Million |
AU$59.65 Million ≈ $42.21 Million |
-4.35pp |
| 2021-06-30 | 46.26% | AU$25.00 Million ≈ $17.69 Million |
AU$54.05 Million ≈ $38.24 Million |
+16.08pp |
| 2020-06-30 | 30.17% | AU$15.00 Million ≈ $10.61 Million |
AU$49.72 Million ≈ $35.18 Million |
-21.86pp |
| 2019-06-30 | 52.03% | AU$6.31 Million ≈ $4.47 Million |
AU$12.13 Million ≈ $8.58 Million |
-9.27pp |
| 2018-06-30 | 61.30% | AU$8.95 Million ≈ $6.34 Million |
AU$14.61 Million ≈ $10.34 Million |
-13.34pp |
| 2017-06-30 | 74.64% | AU$13.19 Million ≈ $9.33 Million |
AU$17.67 Million ≈ $12.51 Million |
-- |
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more